Form 4/A for LUCD Lucid Diagnostics Inc.

Accepted 2025-05-23 00:00:00 ET · period of report 2025-05-20 · accession 0001062993-25-010245 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MA	2025-05-23	2025-05-20+	LUCD	Matheis Dennis	Dir	P - Purchase	$1.31	+350.0K	565.4K	+162%	+$458.3K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-05-21	P	A	129,684	$1.32	532,225	D	—	—	(F2) The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.
2	Common	Common Stock	2025-05-20	P	A	187,098	$1.30	402,541	D	—	—	(F1) The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4. (F4) Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.
3	Common	Common Stock	2025-05-22	P	A	33,218	$1.32	565,443	D	—	—	(F3) The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.